Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Vinorelbine 50mg/5ml solution for infusion vials
0801040R0AAABAB
|
Vinorelbine | Vinorelbine | Malignant Disease and Immunosuppression | No data available |
|
Vinorelbine 80mg capsules
0801040R0AAAEAE
|
Vinorelbine | Vinorelbine | Malignant Disease and Immunosuppression | No data available |
|
Vioform-Hydrocortisone cream
1304000V0BZABCA
|
Vioform-Hydrocortisone | Hydrocortisone | Skin | No data available |
|
Vioform-Hydrocortisone ointment
1304000V0BZACCL
|
Vioform-Hydrocortisone | Hydrocortisone | Skin | No data available |
|
Viokase 16 tablets
010904000BBACA0
|
Proprietary compound preparation BNF 0109040 | Other pancreatin preparations | Gastro-Intestinal System | No data available |
|
Viokase 8 tablets
010904000BBABA0
|
Proprietary compound preparation BNF 0109040 | Other pancreatin preparations | Gastro-Intestinal System | No data available |
|
Vioxx 12.5mg tablets
1001010AFBBACAC
|
Vioxx | Rofecoxib | Musculoskeletal and Joint Diseases | No data available |
|
Vioxx 12.5mg/5ml oral suspension
1001010AFBBAAAA
|
Vioxx | Rofecoxib | Musculoskeletal and Joint Diseases | No data available |
|
Vioxx 25mg tablets
1001010AFBBADAD
|
Vioxx | Rofecoxib | Musculoskeletal and Joint Diseases | No data available |
|
Vioxx 25mg/5ml oral suspension
1001010AFBBABAB
|
Vioxx | Rofecoxib | Musculoskeletal and Joint Diseases | No data available |
|
VioxxAcute 25mg tablets
1001010AFBBAEAD
|
Vioxx | Rofecoxib | Musculoskeletal and Joint Diseases | No data available |
|
VioxxAcute 50mg tablets
1001010AFBBAFAE
|
Vioxx | Rofecoxib | Musculoskeletal and Joint Diseases | No data available |
|
Viracept 250mg tablets
0503010C0BBAAAA
|
Viracept | Nelfinavir mesilate | Infections | No data available |
|
Viracept 50mg/g oral powder
0503010C0BBABAB
|
Viracept | Nelfinavir mesilate | Infections | No data available |
|
Viraferon 18million units/1.2ml inj multidose pens
0802040J0BFADBB
|
Viraferon | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
Viraferon 18million units/3ml inj multidose vials
0802040J0BFACAU
|
Viraferon | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
Viraferon 30million units/1.2ml inj multidose pens
0802040J0BFAEBC
|
Viraferon | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
ViraferonPeg 100microgram inj pre-filled pens
0802040A0BBAIAK
|
ViraferonPeg | Peginterferon alpha | Malignant Disease and Immunosuppression | No data available |
|
ViraferonPeg 100microgram inj pre-filled pens CLEARCLICK
0802040A0BBAPAK
|
ViraferonPeg | Peginterferon alpha | Malignant Disease and Immunosuppression | No data available |
|
ViraferonPeg 100microgram inj vials
0802040A0BBABAB
|
ViraferonPeg | Peginterferon alpha | Malignant Disease and Immunosuppression | No data available |
|
ViraferonPeg 120microgram inj pre-filled pens
0802040A0BBAGAI
|
ViraferonPeg | Peginterferon alpha | Malignant Disease and Immunosuppression | No data available |
|
ViraferonPeg 120microgram inj pre-filled pens CLEARCLICK
0802040A0BBAMAI
|
ViraferonPeg | Peginterferon alpha | Malignant Disease and Immunosuppression | No data available |
|
ViraferonPeg 120microgram inj vials
0802040A0BBAEAE
|
ViraferonPeg | Peginterferon alpha | Malignant Disease and Immunosuppression | No data available |
|
ViraferonPeg 150microgram inj pre-filled pens
0802040A0BBAFAH
|
ViraferonPeg | Peginterferon alpha | Malignant Disease and Immunosuppression | No data available |
|
ViraferonPeg 150microgram inj pre-filled pens CLEARCLICK
0802040A0BBANAH
|
ViraferonPeg | Peginterferon alpha | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.